February 2, 2007 – Molecular Insight Pharmaceuticals placed 5 million shares with investors at $14 each in its IPO. Although $14 was the low end of the range, the more important fact is that the range held, and a $14 price gives the company a stout $344 million market capitalization. Clearly, investors see potential in Molecular Insight, because its clinical candidates are not particularly advanced. At the moment, it has three compounds in clinical trials, two in Phase II tests, the other in Phase I. We look at the compounds in clinical development and at the finances of the company...
